Premium
Somatostatin receptor scintigraphy in the initial staging of Hodgkin's disease
Author(s) -
Van Den AnkerLugtenburg P. J.,
Krenning E. P.,
Oei H. Y.,
Van Hagen M. P.,
Gerrits C. J. H.,
Reubi J. C.,
Lamberts S. W. J.,
Löwenberg B.
Publication year - 1996
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1996.443986.x
Subject(s) - scintigraphy , medicine , stage (stratigraphy) , nuclear medicine , lymphoma , radiology , somatostatin receptor , somatostatin , paleontology , biology
Somatostatin receptor (SS‐R) scintigraphy has been successfully used in the visualization of a variety of neuroendocrine tumours. In vitro studies have shown that SS‐Rs are present in human malignant lymphomas. We conducted a prospective study in 56 consecutive untreated patients with histologically proven Hodgkin's disease (HD) and compared the results of SS‐R scintigraphy with physical and radiological examinations as initial evaluation. SS‐R scintigraphy was positive in 55/56 (98%) patients at sites of documented disease. In 20 patients SS‐R scintigraphy disclosed lymphoma localizations not revealed following procedures of conventional staging. As a result in 12 patients (21%) SS‐R scintigraphy produced a change of stage and in seven patients (13%) the additional information obtained from SS‐R scintigraphy led to a change of treatment. SS‐R scintigraphy failed to visualize sites of HD in four patients, mainly in the abdominal area. In three patients a false‐positive result was obtained. These data show that SS‐R scintigraphy provides an imaging technique that appears to visualize tumours in most patients with HD and may be clinically useful in the management of these patients.